Search Results

You are looking at 31 - 40 of 89 items for :

  • Refine by Access: Content accessible to me x
Clear All
Journal of Psychedelic Studies
Authors:
John M. Clifton
,
Annabelle M. Belcher
,
Aaron D. Greenblatt
,
Christopher M. Welsh
,
Thomas O. Cole
, and
Alan K. Davis

, methamphetamines, heroin, prescription opioids, benzodiazepines, cocaine/crack, LSD, mescaline, mushrooms, DMT, salvia PCP, and MDMA (ecstasy). Perceived risk Participants were asked whether they had ever heard of

Open access

Introduction Psychedelic drugs like lysergic acid diethylamide (LSD-25), 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin are being investigated again, showing therapeutic potential for certain psychological disorders

Open access
Journal of Behavioral Addictions
Authors:
Pedro Romero
,
Andrea Czakó
,
Wim van den Brink
, and
Zsolt Demetrovics

research indicates the potential of psychedelic-assisted therapy (PAT) to treat treatment-resistant mental disorders, including various substance use disorders ( Andersen, Carhart-Harris, Nutt, & Erritzoe, 2021 ). While atypical psychedelics (e.g., MDMA

Open access

treatment assignment can significantly influence both placebo and nocebo effects in psychedelic therapy. In a similar vein, Flameling, Aday, and Van Elk (2023) point out the potential for both placebo and nocebo effects in MDMA trials. It is described that

Open access
Journal of Psychedelic Studies
Authors:
Cody Sykes Gilbert
,
Mitch Earleywine
,
Maha N. Mian
, and
Brianna R. Altman

., 2007 ). Researchers once praised MDMA, which increases activity in both systems, as a potential antidepressant ( Riedlinger & Riedlinger, 1994 ). MDMA-assisted treatment for other disorders appear to help depressive symptoms , though those in the

Open access

, Wiegand, Taitano, & Delgado, 2006 ), end-of-life anxiety ( Griffiths et al., 2016 ), and substance use disorders ( Johnson, Garcia-Romeu, Cosimano, & Griffiths, 2014 ; Sessa et al., 2021 ). Most notably, the FDA designated MDMA-assisted psychotherapy a

Open access

classes: classical psychedelics (e.g. Psilocybin, LSD, DMT), entactogens (e.g. MDMA), dissociative anaesthetics (e.g. Ketamine), and atypical hallucinogens (e.g. Ibogaine). Each of these different classes are characterised by unique pharmacological

Open access

subscales. The MEQ-30 has demonstrated sensitivity in assessing the effects of a range of psychedelic compounds, including LSD ( Schmid & Liechti, 2018 ), MDMA ( Lyvers & Meester, 2012 ), psilocybin ( Barrett et al., 2015 ), ayahuasca ( Schenberg, Tofoli

Open access

, DMT, and other substances, as seen in Table 1 . Table 1. Lifetime use of hallucinogens Hallucinogen Mean (SD) Median Range LSD 27.51 (104.99) 1.00 0–1,000 Mushrooms 25.64 (94.08) 5.00 0–1,000 MDMA 19.55 (82.7) 0.00 0–5 DMT 3.66 (11.21) 0.00 0

Open access
Journal of Psychedelic Studies
Authors:
Thaddeus James Camlin
,
Donald Eulert
,
Arthur Thomas Horvath
,
Steven F. Bucky
,
Joseph P. Barsuglia
, and
Martin Polanco

( Depoortere, 1987 ; Marrosu et al., 1995 ; Schneider & Sigg, 1957 ). If an ibogaine protocol is developed and psychotherapy is a part of it, as it is in the MDMA research protocol ( Mithoefer, 2017 ), then it may be worth considering the inclusion of

Open access